DEA allows anti-legalization pharma corporation to produce synthetic THC

chemicals that mimic the effects of tetrahydrocannabinol (THC).

But mimicking the effects does not mean that it will lead to same results as marijuana. Research on the drug suggests that spice and other forms of synthetic cannabis are capable of producing more intense and prolonged effects at much lower doses than organic cannabis because they affect more of the body and mind.

Announcing that their product is on the market, Insys detailed the treatment possibilities for cancer, AIDS, and other diseases.

Representatives of the company also stated that “Syndros may cause psychiatric and cognitive effects and impair mental and/or physical abilities.”

Advertisement

 

Ryan Beitler
Author: Ryan Beitler

An editor and contributor to Addiction Now, Ryan Beitler is a journalist, fiction writer, musician, and travel writer. He has written for Paste Magazine, OC Weekly, numerous addiction recovery publications, and his travel blog Our Little Blue Rock. He lives in Southern California. Contact Ryan at ryanrbeitler@gmail.com or ryanb@addictionnow.com.

Summary
Article Name
DEA allows anti-legalization pharma corporation to produce synthetic THC
Description
After Insys Therapeutics, a wealthy pharmaceutical company, repeatedly opposed efforts to legalize marijuana, the Drug Enforcement Administration (DEA) approved the company’s proposal to produce synthetic THC.
Author
Ryan Beitler
Publisher Name
Addiction Now